Here is what Chat GPT (AI) thoughts are on the matter of ROW partner for Trofinetide - Global Pharma with a strong focus on CNS disorders !!
Noting that #2 has always been a strong pick of Sillazze from memory.There are several pharmaceutical companies that specialize in the development of treatments for rare central nervous system (CNS) diseases. Some of these companies include:
UniQure: UniQure is a biopharmaceutical company focused on the development of gene therapies for the treatment of CNS diseases.
Roche: Roche is a multinational pharmaceutical company with a strong presence in the CNS disease space. It has a wide portfolio of innovative treatments for various CNS diseases.
Novartis: Novartis is a multinational pharmaceutical company that has a strong focus on the development of treatments for CNS diseases. It has a wide portfolio of innovative treatments for various CNS diseases.
Biogen: Biogen is a biopharmaceutical company that specializes in the development of treatments for CNS diseases. It has a wide portfolio of innovative treatments for various CNS diseases, including Alzheimer's disease and multiple sclerosis.
Sanofi: Sanofi is a multinational pharmaceutical company that has a strong focus on the development of treatments for CNS diseases. It has a wide portfolio of innovative treatments for various CNS diseases.
These are just a few examples of pharmaceutical companies that specialize in the development of treatments for CNS diseases. There are many other companies that are committed to finding treatments for these often-challenging and debilitating conditions.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$20.28 |
Change
0.640(3.26%) |
Mkt cap ! $2.566B | |||
| Open | High | Low | Value | Volume |
| $19.72 | $20.55 | $19.65 | $16.38M | 806.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 655 | $20.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.29 | 102 | 3 |
View Market Depth
| Last trade - 15.08pm 18/09/2025 (20 minute delay) ? |
| NEU (ASX) Chart |